14 completed, 9 recruiting, 8 unknown, 7 active not recruiting. 26 Phase 2, 7 Phase 1, 5 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow this condition Literature Review of Salivary Gland Cancer trials Research Report on Salivary Gland Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-26 | 2026-10-21 |
| DESTINY-PANTUMOUR04 Trastuzumab deruxtecan - Adenocarcinoma (NOS), Anal Cancer | Recruiting | AstraZeneca | 100 | 2025-09-18 | 2026-09-25 | |
| Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) Sacituzumab govitecan - Salivary Gland Cancer, Thyroid Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 32 | 2025-04-15 | 2025-07-25 |
| A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers Ivonescimab - Salivary Gland Cancer, Advanced Salivary Gland Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 35 | 2025-02-26 | 2026-10-21 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Zanidatamab - Breast Cancer, Gastric Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 200 | 2025-01-14 | 2026-07-10 |
| Enhanced Assistance During Radiotherapy for Unmet Essential Needs Standard assistance, Enhanced assistance - Bone Cancer, Brain Cancer | Not applicable | Completed | Washington University School of Medicine | 33 | 2024-10-04 | 2025-08-26 |
| Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers Observation - Salivary Gland Cancer | Unknown | Royal Marsden NHS Foundation Trust | 250 | 2024-09-01 | 2024-08-09 | |
| Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers Implantable Microdevice (IMD) - Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland | Early Phase 1 | Recruiting | Brigham and Women's Hospital | 30 | 2023-11-01 | 2026-01-26 |
| Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC vedicitumomab (Edisil, RC48）, vedicitumomab in combination with pyrrolizidine, RC48 in combination with a platinum-based chemotherapeutic agent - Salivary Gland Cancer | Phase 1 / Phase 2 | Unknown | Peking Union Medical College | 120 | 2023-06-07 | 2023-06-12 |
| Amivantamab in Adenoid Cystic Carcinoma Amivantamab - Salivary Gland Cancer | Phase 2 | Active not recruiting | Trisha Wise-Draper | 21 | 2022-08-05 | 2026-05-08 |
| The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers observation - Head and Neck Cancer, Nasopharynx Cancer | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 13600 | 2022-05-31 | 2026-04-03 | |
| Survival With Patients Treated With Salivary Gland Cancer Surgical intervention with or without postoperative adjuvant therapy - Salivary Gland Cancer, Salivary Gland Neoplasms | Completed | Clinical Center of Vojvodina | 250 | 2022-01-01 | 2022-05-25 | |
| 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma 9-ING-41, Carboplatin, Pembrolizumab - Salivary Gland Cancer, Recurrent Salivary Gland Cancer | Phase 2 | Active not recruiting | Glenn J. Hanna | 32 | 2021-09-17 | 2026-08-07 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy - Salivary Gland Cancer, HER2 Gene Mutation | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-12-24 | 2026-04-13 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
| Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Lenvatinib, Pembrolizumab - Adenoid Cystic Carcinoma, Salivary Gland Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 64 | 2020-06-02 | 2026-10-09 |
| Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Lutetium-177-PSMA-I&T - Salivary Gland Cancer, Salivary Duct Carcinoma | Phase 2 | Completed | Radboud University Medical Center | 12 | 2020-05-26 | 2023-05-10 |
| Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) Darolutamide, Goserelin - Salivary Gland Cancer | Phase 2 | Completed | National Cancer Center Hospital East | 57 | 2020-04-17 | 2026-04-08 |
Showing 20 of 42. Sign in to see all of them.
Salivary Gland Neoplasms (42) · Carcinoma, Adenoid Cystic (14) · Prostatic Neoplasms (10) · Head and Neck Neoplasms (9) · Breast Neoplasms (8) · Ovarian Neoplasms (8) · Pancreatic Neoplasms (8) · Thyroid Neoplasms (8) · Stomach Neoplasms (7) · Colorectal Neoplasms (6) · Endometrial Neoplasms (6) · Esophageal Neoplasms (6) · Uterine Cervical Neoplasms (6) · Anus Neoplasms (5) · Laryngeal Neoplasms (5)
Mouth Diseases (42) · Salivary Gland Diseases (42) · Stomatognathic Diseases (42) · Neoplasms by Site (41) · Mouth Neoplasms (38) · Neoplasms (38) · Head and Neck Neoplasms (33) · Neoplasms by Histologic Type (25) · Neoplasms, Glandular and Epithelial (25) · Carcinoma (23) · Adenocarcinoma (16) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Genital Diseases (12) · Respiratory Tract Diseases (12)
pembrolizumab (5) · Carboplatin (4) · Cisplatin (3) · Docetaxel (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Observation (2) · Ado-Trastuzumab Emtansine (1) · Androgen Antagonists (1) · Biological Therapy (1) · Brachytherapy (1) · CP protocol (1) · Doxorubicin (1) · Drug Therapy (1) · Gefitinib (1) · Goserelin (1)
Radboud University Medical Center (4) · Dana-Farber Cancer Institute (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Memorial Sloan Kettering Cancer Center (2) · University Health Network, Toronto (2) · Actuate Therapeutics Inc. (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Christian von Buchwald (1) · Clinical Center of Vojvodina (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Glenn J. Hanna (1) · Jazz Pharmaceuticals (1) · Klus Pharma Inc. (1) · M.D. Anderson Cancer Center (1)
United States (21) · Netherlands (5) · Italy (3) · Belgium (2) · Canada (2) · Germany (2) · South Korea (2) · Australia (1) · Austria (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · Hungary (1)
Glenn J Hanna, MD (3) · Alan Ho, MD, PhD (2) · Carla ML van Herpen, MD, PhD (2) · Alexander Pearson (1) · Anna Spreafico (1) · Annalisa Trama, MD (1) · Charalampos Floudas, M.D. (1) · Christian Von Buchwald, MD, DMSc (1) · George Blumenschein, MD (1) · Glenn J. Hanna, M.D (1) · Jennifer Johnson, MD, PhD (1) · Jianguo Zhang, Doctor (1) · Joanna Yang, M.D. (1) · Johann De Bono, Prof. Dr. (1) · Jordi Rodon Ahnert, MD, PhD (1)
PMID 34503735, PMID 24585506, PMID 26951097, PMID 29149611, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34920917, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36748723, PMID 36928072, PMID 37620627, PMID 37939426, PMID 39979665, PMID 40121391, PMID 40663212, PMID 41746627, PMID 41920388, PMID 42546251
2015 (1), 2016 (1), R44CA250824 (1)